Research programme: immunotherapeutics - Millennium Pharmaceuticals/Shattuck Labs

Drug Profile

Research programme: immunotherapeutics - Millennium Pharmaceuticals/Shattuck Labs

Alternative Names: Agonist redirected checkpoint fusion proteins - Shuttuck Labs/Takeda; Checkpoint fusion proteins - Shuttuck Labs/Takeda

Latest Information Update: 19 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shattuck Labs; Takeda Oncology
  • Class Antineoplastics; Immunotherapies; Recombinant proteins
  • Mechanism of Action Checkpoint kinase inhibitors; Tumour necrosis factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 10 Aug 2017 Early research in Cancer in USA (unspecified route)
  • 10 Aug 2017 Takeda Oncology and Shattuck Labs agree to co-develop Checkpoint fusion proteins in USA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top